EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Deficiency of mineralocorticoid receptor signalling in myeloid cells protects cardiac and kidney function in hypertensive diabetic mice

Gregory H Tesch iD, Elyce Ozols, James Morgan, Morag J Young, David J Nikolic-Paterson

Clinical Science · 2025

DOI: 10.1042/cs20256132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Science, 2025. Verfasst von Gregory H Tesch und 4 weiteren Autor:innen. Beteiligte Einrichtung: Monash Health (Department of Nephrology), Clayton, Victoria, Australia. Hauptthemen laut MEDLINE: Receptors, Mineralocorticoid, Diabetes Mellitus, Experimental, Hypertension, Kidney. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council of Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mineralocorticoid receptor antagonists (MRAs) reduce hypertension, inflammation and tissue injury in human and experimental diabetes. Inflammation and injury in diabetic hearts and kidneys is also dependent on infiltrating macrophages. Therefore, we hypothesised that the tissue protective effects of MRAs in diabetes are dependent on mineralocorticoid receptor (MR) signalling in macrophages. To evaluate this hypothesis, transgenic mice with intact myeloid MR (MRflox/flox) or myeloid MR deficiency (MRflox/flox LysMCre) were developed on the hypertensive endothelial nitric oxide synthase deficient (Nos3-/-) mouse strain. Groups of these mice were made diabetic with streptozotocin and were assessed after 15 weeks for development of hypertension, cardiomyopathy and nephropathy. Nos3-/- mice with myeloid MR deficiency had equivalent diabetes and hypertension as myeloid MR intact controls but were protected against cardiac and renal function impairment. In diabetic hearts, myeloid MR deficiency reduced cardiomyocyte hypertrophy, capillary loss and fibrosis in association with reduced macrophage accumulation and a switch from an M1 to an M2 macrophage phenotype. In diabetic kidneys, myeloid MR deficiency reduced renal dysfunction (elevated plasma cystatin C) but did not protect against albuminuria, glomerulosclerosis or tubular damage; this was associated with a partial reduction in glomerular macrophages and an M1 to M2 macrophage phenotype switch. Therefore, MR signalling in macrophages promotes dysfunction in the diabetic heart and kidneys of Nos3-/- mice without affecting hypertension. Furthermore, abolishing macrophage MR signalling provides greater protection to hearts than kidneys during type 1 diabetes and hypertension, giving new insight into the mechanisms by which MRAs suppress tissue injury during diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, MineralocorticoidDiabetes Mellitus, ExperimentalHypertensionKidneyDiabetic NephropathiesMyeloid CellsDiabetic CardiomyopathiesAnimalsSignal TransductionMacrophagesMice, KnockoutNitric Oxide Synthase Type IIIMaleMiceMineralocorticoid Receptor AntagonistsMyocardiumMice, TransgenicMice, Inbred C57BLFibrosis

Stichwörter der Autor:innen

diabetic cardiomyopathydiabetic nephropathyfibrosismacrophagemineralocorticoid receptor

Substanzen

Receptors, MineralocorticoidNitric Oxide Synthase Type IIINos3 protein, mouseMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Monash Health (Department of Nephrology), Clayton, Victoria, Australia.
  • Monash University School of Clinical Sciences at Monash Health, Clayton, Victoria, Australia.
  • Monash University Centre for Inflammatory Diseases, Clayton, Victoria, Australia.
  • Hudson Institute of Medical Research, Clayton, Victoria, Australia.
  • Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
  • Baker Department of Cardiometabolic Health and Disease, University of Melbourne, Victoria, Australia.

ORCID-Profile: Gregory H Tesch

Förderung

  • National Health and Medical Research Council of Australia

Zitieren

APA

Tesch, G. H., Ozols, E., Morgan, J., Young, M. J., & Nikolic-Paterson, D. J. (2025). Deficiency of mineralocorticoid receptor signalling in myeloid cells protects cardiac and kidney function in hypertensive diabetic mice. Clinical Science. https://doi.org/10.1042/cs20256132

Vancouver

Tesch GH, Ozols E, Morgan J, Young MJ, Nikolic-Paterson DJ. Deficiency of mineralocorticoid receptor signalling in myeloid cells protects cardiac and kidney function in hypertensive diabetic mice. Clinical Science. 2025. doi:10.1042/cs20256132

BibTeX
@article{Tesch2025,
  author = {Tesch, Gregory H and Ozols, Elyce and Morgan, James and Young, Morag J and Nikolic-Paterson, David J},
  title = {Deficiency of mineralocorticoid receptor signalling in myeloid cells protects cardiac and kidney function in hypertensive diabetic mice},
  journal = {Clinical Science},
  year = {2025},
  doi = {10.1042/cs20256132}
}
Kostenlos starten →